display
Berlin / Tübingen (dpa) - According to a media report, the Tübingen-based company CureVac and the chemical group Bayer want to work together on the further development, production and sale of a corona vaccine.
The aim is to be able to put the vaccine on the market as quickly and widely as possible after approval, reported the news portal “ThePioneer” (Thursday).
The report was confirmed to the German Press Agency in government circles.
Such a “national vaccination alliance” could accelerate the vaccination situation in Germany and help that everyone who wanted it would be vaccinated by the summer, writes “ThePioneer”.
According to this report, a corresponding cooperation was the subject of a conversation between Chancellor Angela Merkel with Health Minister Jens Spahn, Economics Minister Peter Altmaier, Chancellor Helge Braun (all CDU) and Vice Chancellor Olaf Scholz (SPD) on Wednesday morning.
Accordingly, the biotechnology company should benefit from the organizational and logistics power of the chemical company.
A production of the Curevac vaccine in a US Bayer plant is also under discussion, it said.
In December, CureVac received the green light to start its pivotal Phase III clinical trial.
According to a spokesman, CureVac expects the first results of the study at the end of the first quarter of 2021. For the planned market launch of the vaccine against Covid-19, in addition to an extension of the manufacturing license, approval by the EU Commission is required.